Evaluation of folliculogenesis and oxidative stress parameters in type 1 diabetes mellitus women with different glycemic profiles.
Anti-Müllerian hormone
Continuous glucose monitoring
Glucotypes
Ovarian follicular apparatus
Oxidative stress
Type 1 diabetes mellitus
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
06 Jun 2024
06 Jun 2024
Historique:
received:
09
01
2024
accepted:
26
03
2024
medline:
6
6
2024
pubmed:
6
6
2024
entrez:
6
6
2024
Statut:
aheadofprint
Résumé
Despite enormous advances in diabetes treatment, women with type 1 diabetes mellitus (DM) still experience delayed menarche, menstrual irregularities, fewer pregnancies, and a higher rate of stillbirths compared to women without the disease. Due to the fact that type 1 DM occurs at a young age, the preservation of reproductive health is one of the most important goals of treatment. The aim of this study was to evaluate the relationship between different glycemic profiles and changes in the pro-oxidant-antioxidant balance and ovarian follicular apparatus in reproductive-age patients with type 1 DM. We examined 50 reproductive-age (19-38 years) women with type 1 DM with a disease duration of at least ten years. Carbohydrate metabolism was assessed with the continuous glucose monitoring (CGM) system and glycated hemoglobin (HbA1c) concentration measurement. CGM was performed using the FreeStyle Libre flash glucose monitoring system (Abbott Diabetes Care, Witney, UK). In each patient, malondialdehyde level, catalase activity and 3-nitrotyrosine level in the blood serum were determined. To assess the ovarian function, we measured the ovarian volume, the antral follicle count, and the serum levels of anti-Müllerian hormone and follicle-stimulating hormone. All patients were divided into four groups (glucotypes) based on the CGM results. Group 1 included type 1 DM patients with satisfactory compensation of carbohydrate metabolism; group 2 consisted of patients with frequent hypoglycemic conditions and pathological glucose variability; group 3 included individuals with prolonged hyperglycemic conditions and maximum HbA1c levels; and group 4 comprised patients with the glycemic profile characterized by all the presented types of dysglycemia (intermittent glycemia). We revealed a negative correlation between serum catalase activity and time of hypoglycemic conditions in patients with type 1 DM based on the CGM results (r The data obtained indicate the relationship between the ovarian volume, serum anti-Müllerian hormone level, the antral follicle count and oxidative stress parameters not only in patients with hyperglycemia, but also in those with hypoglycemic conditions, as well as with pathological glucose variability.
Sections du résumé
BACKGROUND
BACKGROUND
Despite enormous advances in diabetes treatment, women with type 1 diabetes mellitus (DM) still experience delayed menarche, menstrual irregularities, fewer pregnancies, and a higher rate of stillbirths compared to women without the disease. Due to the fact that type 1 DM occurs at a young age, the preservation of reproductive health is one of the most important goals of treatment.
AIMS
OBJECTIVE
The aim of this study was to evaluate the relationship between different glycemic profiles and changes in the pro-oxidant-antioxidant balance and ovarian follicular apparatus in reproductive-age patients with type 1 DM.
METHODS
METHODS
We examined 50 reproductive-age (19-38 years) women with type 1 DM with a disease duration of at least ten years. Carbohydrate metabolism was assessed with the continuous glucose monitoring (CGM) system and glycated hemoglobin (HbA1c) concentration measurement. CGM was performed using the FreeStyle Libre flash glucose monitoring system (Abbott Diabetes Care, Witney, UK). In each patient, malondialdehyde level, catalase activity and 3-nitrotyrosine level in the blood serum were determined. To assess the ovarian function, we measured the ovarian volume, the antral follicle count, and the serum levels of anti-Müllerian hormone and follicle-stimulating hormone. All patients were divided into four groups (glucotypes) based on the CGM results. Group 1 included type 1 DM patients with satisfactory compensation of carbohydrate metabolism; group 2 consisted of patients with frequent hypoglycemic conditions and pathological glucose variability; group 3 included individuals with prolonged hyperglycemic conditions and maximum HbA1c levels; and group 4 comprised patients with the glycemic profile characterized by all the presented types of dysglycemia (intermittent glycemia).
RESULTS
RESULTS
We revealed a negative correlation between serum catalase activity and time of hypoglycemic conditions in patients with type 1 DM based on the CGM results (r
CONCLUSIONS
CONCLUSIONS
The data obtained indicate the relationship between the ovarian volume, serum anti-Müllerian hormone level, the antral follicle count and oxidative stress parameters not only in patients with hyperglycemia, but also in those with hypoglycemic conditions, as well as with pathological glucose variability.
Identifiants
pubmed: 38842765
doi: 10.1007/s12020-024-03805-4
pii: 10.1007/s12020-024-03805-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : 1021062812154-3-3.2.2
Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : 1021062812154-3-3.2.2
Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : 1021062812154-3-3.2.2
Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : 1021062812154-3-3.2.2
Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : 1021062812154-3-3.2.2
Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : 1021062812154-3-3.2.2
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
M. Mobasseri, M. Shirmohammadi, T. Amiri, N. Vahed, H. Hosseini Fard, M. Ghojazadeh, Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot. Perspect. 10, 98–115 (2020). https://doi.org/10.34172/hpp.2020.18
doi: 10.34172/hpp.2020.18
pubmed: 32296622
pmcid: 7146037
E.S. Strotmeyer, A.R. Steenkiste, T.P. Foley Jr., S.L. Berga, J.S. Dorman, Menstrual cycle differences between women with type 1 diabetes and women without diabetes. Diabetes Care 26, 1016–1021 (2003). https://doi.org/10.2337/diacare.26.4.1016
doi: 10.2337/diacare.26.4.1016
pubmed: 12663566
E. Codner, P.M. Merino, M. Tena-Sempere, Female reproduction and type 1 diabetes: from mechanisms to clinical findings. Hum. Reprod. Update 18, 568–585 (2012). https://doi.org/10.1093/humupd/dms024
doi: 10.1093/humupd/dms024
pubmed: 22709979
E. Codner, H.F. Escobar-Morreale, Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 92, 1209–1216 (2007). https://doi.org/10.1210/jc.2006-2641
doi: 10.1210/jc.2006-2641
pubmed: 17284617
X. Gaete, M. Vivanco, F.C. Eyzaguirre, P. Lopez, H.K. Rhumie, N. Unanue, E. Codner, Menstrual cycle irregularities and their relationship with HbA1c and insulin dose in adolescents with type 1 diabetes mellitus. Fertil. Steril. 94, 1822–1826 (2010). https://doi.org/10.1016/j.fertnstert.2009.08.039
doi: 10.1016/j.fertnstert.2009.08.039
pubmed: 19796762
M.G. Tolpygina, M.A. Tarasova, N.V. Borovik, E.V. Misharina, A.V. Tiselko, The influence of compensation of carbohydrate metabolism on the restoration of ovulatory function in women of reproductive age with type 1 diabetes. J. Obst. Women’s Dis. 67, 42–49 (2018). https://doi.org/10.17816/JOWD67542-49
doi: 10.17816/JOWD67542-49
T. Battelino, N. Danne, R.M. Bergenstal et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42, 1593–1603 (2019). https://doi.org/10.2337/dci19-0028
doi: 10.2337/dci19-0028
pubmed: 31177185
pmcid: 6973648
C.R. Marling, N.W. Struble, R.C. Bunescu, J.H. Shubrook, F.L. Schwartz, A consensus perceived glycemic variability metric. J. Diabetes Sci. Technol. 7, 871–879 (2013). https://doi.org/10.1177/193229681300700409
doi: 10.1177/193229681300700409
pubmed: 23911168
pmcid: 3879751
R.W. Beck, T. Riddlesworth, K. Ruedy et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND Randomized Clinical Trial. JAMA 317, 371–378 (2017). https://doi.org/10.1001/jama.2016.19975
doi: 10.1001/jama.2016.19975
pubmed: 28118453
K.D. Kohnert, P. Heinke, G. Fritzsche, L. Vogt, P. Augstein, E. Salzsieder, Evaluation of the mean absolute glucose change as a measure of glycemic variability using continuous glucose monitoring data. Diabetes Technol. Ther. 15, 448–454 (2013). https://doi.org/10.1089/dia.2012.0303
doi: 10.1089/dia.2012.0303
pubmed: 23550553
J. Bolinder, R. Antuna, P. Geelhoed-Duijvestijn, J. Kröger, R. Weitgasser, Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 388, 2254–2263 (2016). https://doi.org/10.1016/S0140-6736(16)31535-5
doi: 10.1016/S0140-6736(16)31535-5
pubmed: 27634581
I.B. Hirsch, Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care 38, 1610–1614 (2015). https://doi.org/10.2337/dc14-2898
doi: 10.2337/dc14-2898
pubmed: 26207054
A.M. Gomez, D.C. Henao, A. Imitola Madero et al. Defining high glycemic variability in type 1 diabetes: comparison of multiple indexes to identify patients at risk of hypoglycemia. Diabetes Technol. Ther. 21, 430–439 (2019). https://doi.org/10.1089/dia.2019.0075
doi: 10.1089/dia.2019.0075
pubmed: 31219350
A.L. McCall, B.P. Kovatchev, The median is not the only message: a clinician’s perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus. J. Diabetes Sci. Technol. 3, 3–11 (2009). https://doi.org/10.1177/193229680900300102
doi: 10.1177/193229680900300102
pubmed: 19756168
pmcid: 2743494
A.V. Tiselko, Risk factors for the development of pathological glucose variability in pregnant women with type 1 diabetes mellitus. J. Obstet. Womens Dis 68, 41–50 (2019). https://doi.org/10.17816/JOWD68341-50
doi: 10.17816/JOWD68341-50
A. Ceriello, A. Novials, E. Ortega, S. Canivell, L. La Sala, G. Pujadas, K. Esposito, D. Giugliano, S. Genovese, Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 36, 2346–2350 (2013). https://doi.org/10.2337/dc12-2469
doi: 10.2337/dc12-2469
pubmed: 23564922
pmcid: 3714509
K.G. Maier, X. Han, B. Sadowitz, K.L. Gentile, F.A. Middleton, V. Gahtan, Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia. J. Vasc. Surg. 51, 1238–1247 (2010). https://doi.org/10.1016/j.jvs.2009.11.073
doi: 10.1016/j.jvs.2009.11.073
pubmed: 20299182
J.L. Kim, E.F. La Gamma, T. Estabrook, N. Kudrick, B.B. Nankova, Whole genome expression profiling associates activation of unfolded protein response with impaired production and release of epinephrine after recurrent hypoglycemia. PLoS One 12, e0172789 (2017). https://doi.org/10.1371/journal.pone.0172789
doi: 10.1371/journal.pone.0172789
pubmed: 28234964
pmcid: 5325535
Y. Mao, K.X.Q. Tan, A. Seng, P. Wong, S.A. Toh, A.R. Cook, Stratification of patients with diabetes using continuous glucose monitoring profiles and machine learning. Health Data Sci. 2022, 9892340 (2022). https://doi.org/10.34133/2022/9892340
doi: 10.34133/2022/9892340
pubmed: 38487483
pmcid: 10880155
T. Valente, A.K. Arbex, Glycemic variability, oxidative stress, and impact on complications related to type 2 diabetes mellitus. Curr. Diabetes Rev. 17(7), e071620183816 (2021). https://doi.org/10.2174/1573399816666200716201550
doi: 10.2174/1573399816666200716201550
pubmed: 32674737
M.A. Darenskaya, L.I. Kolesnikova, S.I. Kolesnikov, Oxidative stress: pathogenetic role in diabetes mellitus and its complications and therapeutic approaches to correction. Bull. Exp. Biol. Med. 171(2), 179–189 (2021). https://doi.org/10.1007/s10517-021-05191-7
doi: 10.1007/s10517-021-05191-7
pubmed: 34173093
pmcid: 8233182
K. Stadler, Oxidative stress in diabetes. Adv. Exp. Med. Biol. 771, 272–287 (2012). https://doi.org/10.1007/978-1-4614-5441-0_21
doi: 10.1007/978-1-4614-5441-0_21
pubmed: 23393685
S.J. Hamilton, G.F. Watts, Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev. Diabet Stud. 10, 133–156 (2013).
doi: 10.1900/RDS.2013.10.133
pubmed: 24380089
pmcid: 4063100
M. Grabia, K. Socha, J. Soroczyńska, A. Bossowski, R. Markiewicz-Żukowska, Determinants related to oxidative stress parameters in pediatric patients with type 1 diabetes mellitus. Nutrients 15, 2084 (2023). https://doi.org/10.3390/nu15092084
doi: 10.3390/nu15092084
pubmed: 37432230
pmcid: 10180949
R.V. Kapustin, O.N. Arzhanova, A.V. Tiselko, Oxidative stress in pregnant women with diabetes mellitus. Diabetes 20, 461–471 (2017). https://doi.org/10.14341/DM8669
doi: 10.14341/DM8669
U. Asmat, K. Abad, K. Ismail, Diabetes mellitus and oxidative stress-A concise review. Saudi Pharm. J. 24(5), 547–553 (2016). https://doi.org/10.1016/j.jsps.2015.03.013
doi: 10.1016/j.jsps.2015.03.013
pubmed: 27752226
S. Dinić, J. Arambašić Jovanović, A. Uskoković, M. Mihailović, N. Grdović, A. Tolić, J. Rajić, M. Đorđević, M. Vidaković, Oxidative stress-mediated beta cell death and dysfunction as a target for diabetes management. Front Endocrinol. 13, 1006376 (2022). https://doi.org/10.3389/fendo.2022.1006376
doi: 10.3389/fendo.2022.1006376
C. Tatone, F. Amicarelli, The aging ovary-the poor granulosa cells. Fertil. Steril. 99, 12–17 (2013). https://doi.org/10.1016/j.fertnstert.2012.11.029
doi: 10.1016/j.fertnstert.2012.11.029
pubmed: 23273984
N.A. ElSayed, G. Aleppo, V.R. Aroda, et al., on behalf of the American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care 46, S19–S40 (2023). https://doi.org/10.2337/dc23-S002 .
T. Danne, R. Nimri, T. Battelino et al. International consensus on use of continuous glucose monitoring. Diabetes Care 40, 1631–1640 (2017). https://doi.org/10.2337/dc17-1600
doi: 10.2337/dc17-1600
pubmed: 29162583
pmcid: 6467165
L. Góth, A simple method for determination of serum catalase activity and revision of reference range. Clin. Chim. Acta. 196, 143–151 (1991). https://doi.org/10.1016/0009-8981(91)90067-m
doi: 10.1016/0009-8981(91)90067-m
pubmed: 2029780
Diabetes care and research in Europe: the Saint Vincent declaration. Diabet. Med. 7, 360 (1990). https://doi.org/10.1111/j.1464-5491.1990.tb01405.x
C. Kim, R.L. Dunn, B. Braffett, P.A. Cleary, V. Arends, M. Steffes, M.S. Lanham, J.F. Randolph, H. Wessells, M.F. Wellons, A.V. Sarma, EDIC Research Group. Ovarian reserve in women with Type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabet Med 33, 691–692. https://doi.org/10.1111/dme.13072
E. Codner, G. Iniguez, I.M. Hernandez, P. Lopez, H.K. Rhumie, C. Villarroel, R.A. Rey, Elevated anti-Müllerian hormone (AMH) and inhibin B levels in prepubertal girls with type 1 diabetes mellitus. Clin. Endocrinol. 74, 73–78 (2011). https://doi.org/10.1111/j.1365-2265.2010.03887.x
doi: 10.1111/j.1365-2265.2010.03887.x
A.R. Kwon, S. Lee, H.W. Chae, D.H. Kim, H.S. Kim, Frequencies and related factors for microvascular complications in patients with type 1 diabetes. Ann. Pediatr. Endocrinol. Metab. 17, 16–26 (2012). https://doi.org/10.6065/apem.2012.17.1.16
doi: 10.6065/apem.2012.17.1.16
Y. Yi, H. Denic-Roberts, D. Rubinstein, T.J. Orchard, T. Costacou, Effect of age at menarche on microvascular complications among women with Type 1 diabetes. Diabet. Med. 36, 1287–1293 (2019). https://doi.org/10.1111/dme.13936
doi: 10.1111/dme.13936
pubmed: 30784109
F.P. Pralong, Insulin and NPY pathways and the control of GnRH function and puberty onset. Mol. Cell. Endocrinol. 324, 82–86 (2010). https://doi.org/10.1016/j.mce.2010.01.037
doi: 10.1016/j.mce.2010.01.037
pubmed: 20138117
A. Szadkowska, I. Pietrzak, B. Mianowska, J. Bodalska-Lipińska, H.A. Keenan, E. Toporowska-Kowalska, W. Młynarski, J. Bodalski, Insulin sensitivity in Type 1 diabetic children and adolescents. Diabet. Med. 25, 282–288 (2008). https://doi.org/10.1111/j.1464-5491.2007.02357.x
doi: 10.1111/j.1464-5491.2007.02357.x
pubmed: 18279410
H. Escobar-Morreale, M. Roldan-Martin, Type 1 diabetes and polycystic ovary syndrome: systematic review and meta-analysis. Diabetes Care 39, 639–648 (2016). https://doi.org/10.2337/dc15-2577
doi: 10.2337/dc15-2577
pubmed: 27208367
J.H. DeVries, Glucose variability: where it is important and how to measure it. Diabetes 62, 1405–1408 (2013). https://doi.org/10.2337/db12-1610
doi: 10.2337/db12-1610
pubmed: 23613566
pmcid: 3636643
Z. Zhou, B. Sun, S. Huang, C. Zhu, M. Bian, Glycemic variability: adverse clinical outcomes and how to improve it?. Cardiovasc. Diabetol. 19, 102 (2020). https://doi.org/10.1186/s12933-020-01085-6
doi: 10.1186/s12933-020-01085-6
pubmed: 32622354
pmcid: 7335439
E.E. Dubinina, A.V. Pustygina, Oxidative modification of proteins, its role in pathologic states. Ukr. Biokhim. Zh. 80, 5–18 (2008)
M. Murri, M. Luque-Ramírez, M. Insenser, M. Ojeda-Ojeda, H.F. Escobar-Morreale, Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update 19, 268–288 (2013). https://doi.org/10.1093/humupd/dms059
doi: 10.1093/humupd/dms059
pubmed: 23303572
Z. Kurdoglu, H. Ozkol, Y. Tuluce, I. Koyuncu, Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome. J. Endocrinol. Invest. 35, 317–321 (2012).
pubmed: 21521935
C. Mas-Bargues, C. Escrivá, M. Dromant, C. Borrás, J. Viña, Lipid peroxidation as measured by chromatographic determination of malondialdehyde. Human plasma reference values in health and disease. Arch. Biochem. Biophys. 709, 108941 (2021). https://doi.org/10.1016/j.abb.2021.108941
doi: 10.1016/j.abb.2021.108941
pubmed: 34097903
J.S. Reis, C.A. Veloso, C.M. Volpe, J.S. Fernandes, E.A. Borges, C.A. Isoni, P.M. Dos Anjos, J.A. Nogueira-Machado, Soluble RAGE and malondialdehyde in type 1 diabetes patients without chronic complications during the course of the disease. Diab. Vasc. Dis. Res. 9, 309–314 (2012). https://doi.org/10.1177/1479164111436316
doi: 10.1177/1479164111436316
pubmed: 22337892
A.A. Alghobashy, U.M. Alkholy, M.A. Talat, N. Abdalmonem, A. Zaki, I.A. Ahmed, R.H. Mohamed, Trace elements and oxidative stress in children with type 1 diabetes mellitus. Diabetes Metab. Syndr. Obes. 11, 85–92 (2018). https://doi.org/10.2147/DMSO.S157348
doi: 10.2147/DMSO.S157348
pubmed: 29618936
pmcid: 5875397